Individual compoundsCategoriesResearch SetsMembershipJournalSign in
← Journal

The Hypothesis

Mixed / Evolving Human Evidence

NAD+: What Human Trials Actually Show

2–25 min read

Few molecules have become as closely associated with contemporary longevity research as NAD+. Nicotinamide adenine dinucleotide participates in cellular redox reactions and serves as a substrate for enzymes including sirtuins and PARPs.

Preclinical research linking NAD metabolism with ageing generated considerable interest in strategies designed to increase NAD availability. The human evidence is more nuanced.

Randomized human trials have demonstrated that precursors including nicotinamide riboside and nicotinamide mononucleotide can alter circulating NAD-related metabolites. One trial in healthy middle-aged and older adults found chronic nicotinamide riboside supplementation well tolerated and effective at elevating NAD+ levels. A separate randomized trial in postmenopausal women with prediabetes found that nicotinamide mononucleotide increased skeletal-muscle insulin sensitivity.

But increasing a biomarker or a single metabolic measure, and improving human ageing broadly, are different scientific questions. Some trials have reported changes across selected metabolic, physical-performance, inflammatory or sleep-related measures. Others have failed to demonstrate meaningful improvements across various physiological endpoints.

A 2023 systematic review of NAD-related interventions across clinical conditions described a literature in which modulation of NAD metabolism is increasingly well demonstrated while broader clinical outcomes remain heterogeneous and inconsistently measured across trials.

That distinction matters. The scientific question is no longer simply: can NAD availability be altered? Increasingly it is: when, where, in whom, and does doing so produce a meaningful physiological outcome? Neither published human trial base yet supports an inference of extended human lifespan.

Research Status

Extensive preclinical research and a growing body of randomized human trials confirm that NAD+ status can be modified. Broader clinical, functional and longevity implications remain under investigation and are not yet established.

Selected Research

Related Research